The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Still four IPO / exits to go ninja. WLL wouldn't have come under IPO or trade exit. Maybe in three years time though.
The funding document for Weardale Lithium Ltd suggests it is a year or so behind Cornish Lithium (probably 18 months to be realistic) who are valued at £80m. That suggest that WLL will be worth 7p plus a share excluding the warrants MAC hold over them.
MAC have other Weardale Lithium's on their books too. Future biogas - the biggest biogas producer in the UK and currently looking to raise around £35m and no doubt MAC are involved in that as advisors. How much will that be worth ... another initial £1.5m ?
Then there is fast2fibre which has patented technology for fire optics infrastructure that needs replacing on a large scale. Apparently they are in the frame for a large contract in Germany.
Then there is the 4% stake in the Burgh Hotel which has had multi million renovations. Perhaps a trade exit there unless they plan to list and, with low priced warrants exercised, perhaps another £800,000 to £1m to add to the balance sheet.
Over time I expect to see MAC trading in the 10p to 20p range. That's just based on the above and excludes the strong pipeline of investments they alluded to in the recent set of results. Early stage with the impending listing of Future Biogas then maybe 5p to 6p.
The market has yet to cotton on to the fact that MAC has been picking up stakes in the renewable / green energy sector for zero cost, zero dilution in exchange for its advisory services and will continue to repeat this business model with its pipeline..
Market yet to cotton on that MAC have a £1.5m lithium stake in for free.
Market cap £1.6m . 8.7% stake in Weardale Lithium (WLL). These are founder shares and just based on the funding round and you'd expect the value of WLL to be at a premium to funds raised. Cornish Lithium did a crowd funding at an £80m valuation and the £6m target was raised in 15 minutes. It's a hot sector.
Last month MAC flagged up four IPO's / trade exits anticipated within the next 3 to 18 months so I wonder if they are clearing the decks for a RTO by WLL or it's just a good business model where they select companies ripe for future IPO / trade exits. Either way, MAC looks significantly under-valued.
Minoan should have a decent move up tomorrow so, with the greatest of respect, I think this is the 'Fact' you were grasping for:-
https://www.independent.co.uk/sport/football/premier-league/arsenal-bottom-of-the-premier-league-after-stunning-defeat-by-west-ham-10447480.html
Excellent news Bigwil and thanks for posting.
The Cavo Sidero project can be classified as a 'strategic investment' under the criteria of this new legislation. It's an environmentally friendly project and fits all the other criteria. That means MIN should be able to attract additional and significant interest.
The new Greek Govt package is full of incentives including full tax breaks that are game changing for overseas investors in Greece and of course , more importantly here, Min's project. I see this as being the catalyst for the end game now and at an absurdly 5.9m m/cap in relation to a consistent (over the years) nav of 47m euros then the risk/reward is enticing.
I expect to see a renewed demand for the shares when markets re-open this coming week now that this draft legislation has been published. Ultimately, I think the share price range on successful conclusion and an offer for MIN or its subsidiary, Loyalward, ranges from an ultra conservative 3p a share to a perhaps over optimistic 10p. As I say, a highly enticing risk/reward.
They can report larger buys and sells late, sometimes days later. In this instance it would have been a worked buy or sell with a limit price and filled or partly filled by close hence the after hours time.
My guess is it was a buy but if it was a sell it was a good price and highlights an earlier post that said the 100 share trades indicate they mm's want shares. As I say, these things are interesting but for me a side show to the main story.
Looks as if someone put in a limit order and got filled at 1.902 with 2,133,723 shares by close.
noworever, there were several 100 share trades throughout the day. Some traders think they are meaningful signal just like a 1 trade is supposed to be. I'd tend to ignore them as just as it could be a signal it could be a trader wanting to create an impression it is a news signal. Much better to just do your research and ignore the white noise of bulletin boards and things like supposed signals. That said (just to contradict myself!) there were quite a few 100 share trades and other small trades today which is unusual. Fingers crossed for good news soon.
Pokerchips, that's interesting about IMM and it has failed a couple of times now in trials. I'll take another look but last time gave it a wide berth. There were one or two pharma gurus who said the science didn't stack up. They were right last time so I'd suggest its history and perhaps chance of success is responsible for the valuation. Sometimes these things can create opportunities... once bitten etc. I'd say it sounds very high risk but without looking at how it has been revised then that's just an instinctive reaction.
Yes, I think twitter beings out a lot of one line deramping and ramping alike. Your views are always considered with supporting facts which is always good to see. Timing and sentiment is everything and I think inevitably with something like MXC the ramping crew will get in short-term. I've usually done okay when I've got in ahead of the herd especially when the prospects for a headline grabbing trial result such as MXC have are there.
The one thing that put me off MXC was the CLN's but I've taken the view that firstly, the share price might have formeda base and, secondly, even CLN's become meaningless if a successful trial result on Covid is announced and that brings new investor focus and some credibility to the other trials. I don't think they could have picked more publicity generating applications than Covid, brain cancer, Alzheimer's and dementia.
We will see and good luck in your investments as well. I quite like the look of Evgen Pharma as they are fully funded for a bit but I can't see to much to drive the stock forward for a bit aside from a private investor taking a sizeable stake.
Good post shandypants and thanks for sharing. The information should be in the annual report in due course but it's poor if they don't share or reply properly.
BRSD is on my watchlist as potentially it looks like a high growth stock. I believe Justin Waite, who does pretty well with the small caps was interested but he seems to have moved on. Perhaps he found management a bit too reticent to engage as well.
The CEO seems to be bullish and willing to do media interviews so he should realise small cap shares rely on retail investors so good communication goes hand in hand with a healthy share price. I was in a (very) small cap (Starcom) and the FD was disinterested in their AGM slumped in his chair and playing on his phone. I sold - the Company may do very well going forward but I place a lot of weight in how directors engage with their shareholders.
Potentially, it does look like BRSD revenues could grow very quickly. It doesn't bother me that the Company invariably can't give the name of a client just as long as they update with the value and some information about the size of the client and the sector.
As I say, I like the look of BRSD and may invest when I can free up cash from other investments but outstanding low priced warrants can be a drag on the share price so I'll take a look to see how may are around and their expiry date(s).
Pokerchips, I take it you are risk free of Covid? :-) Sorry that was literally below the belt.
It's none of my business but I guess you must have lost money on the stock. We all have had a few of those with wrong timing or wrong decision making but, in my case, I just move on or, on occasions, average down. You seem to have an engrained negative slant and spend a fair amount of time posting on a Company where you seemingly have no financial interest. Welcome to the world where pharmas use cash. Some soar and some crash but it is invariably on their results in clinical trials as opposed to cash burn - within reason. Just as oil stocks crash when they fail to strike after a drill.
You seem smart enough so I assume you know that already but, for whatever reason, you are trying to assess a pharma in the same manner as someone would for a engineering generic widget making company with (unlike MXC) no prospect of high growth or a globally beneficial medical break through.
I would have been reluctant to invest at the 8p dizzy heights, primarily because I try it get in a what I perceive to be ground floor levels. £50m m/cap for a pharma company that has advanced clinical trials for high value market sectors seems far too cheap and I expect the anomaly to be rectified as the phase 3 clinical trial progresses. It will attract a lot of short(ish) term investors.
Regarding profitability it's a little early.
Because MXC is revenue producing there seems to be a lack of recognition that the Company has a substantive pharma element to it. Pharma plays are valued very differently. I think pokerchips is mistaking MXC for some pure generic healthy living / nutritional products play.
Synairgen, for example, has a phase 2 trial relating to Covid and has a £300m plu sm/cap and lost circa £14m last financial year.
MXC has a phase 3 Covid related trial with results in the Autumn. It has clinical trials for brain cancer, dementia and Alzheiner's Disease. Yet the m/cap is a shade over £50m.
In many ways MCX is much safer and attractive than a pure pharma play because it is selling products and increasing revenues. The CEO recently anticipated CimetrA being on sale this year which should boost revenues and progress towards profitability significantly. A significant amount of the work that will enhance revenues is grant funded has been pointed out in earlier posts.
The main point though is that MXC has pharma trials in areas with substantive market size and where new therapies are much needed such as brain cancer where the current treatments are very limited. Ironically, perhaps if MCX were a pure pharma with heavy losses and without other revenue strings to its bow it would get the premium values that others pharmas do.
The m/cap looks seems somewhat of a misnomer when you look at the Company in that context. I think this low valuation anomaly will be corrected if the Covid phase 3 trials are successful and pharmas often have a run up in the share price prior to clinical trial results. Not long to wait (in pharma timescales it's like the blink of an eye) and I'm anticipating a good run up as the phase 3 trial get close to completion and the results are released. There should be plenty of other newsflow as well.
Pokerchips , good to have a civil discussion with you . There are of course bear points and bull points with the Company as indeed applies to every stock - particularly on AIM. I think the bull points over the next six months outweigh the negatives with MXC but respect your views.
In terms of revenues and timescales, they may be a bit optimistic but I see the CEO anticipate CimetrA being on sale this year.
With such poor prognosis for most brain cancer patients I hope and expect the Company will be allowed to accelerate the development where, relatively early stage though it may be, they state "we have been able to achieve amazing results on CBG and CBD in targeting the stem cells" without having to do any invasive surgery. See below:-
https://cannabiswealth.co.uk/2021/07/29/mgc-pharma-discusses-drug-delivery-innovation/
That's fine but you tried to suggest that the results would not be released as there had to be a three month evaluation. That's misleading as there will be results about one month following the completion of the main trial. The three months, as you reference in your subsequent post, is a sub trial to monitor post Covid syndrome symptoms. What I guess is colloquially known as 'long Covid'.
I normally buy and hold but I don't necessarily see this as a long year or so hold but a reasonable risk/reward for the coming months of this year . That's based on the good results from phase two of the CimetrA trial and a decent prospect of a favourable phase 3 clinical trial.
There is also the phase 2 results CogniCann(R) - Phase II clinical trial evaluating the impact on dementia and Alzheimer's Disease patients. That should complete Q4.
Plenty of newsflow to come. I am not a big fan of investing in Company's with CLN's but any positive news from the CimetrA trial should outweigh that negative. I wouldn't be surprised to see a run-up in anticipation of the CimetrA results.
That's fine but you tried to suggest that the results would not be released as there had to be a three month evaluation. That's misleading as there will be results about one month following the completion of the main trial. The three months, as you reference in your subsequent post, is a sub trial to monitor post Covid syndrome symptoms. What I guess is colloquially known as 'long Covid'.
I normally buy and hold but I don't necessarily see this as a long year or so hold but a reasonable risk/reward for the coming months of this year . That's based on the good results from phase two of the CimetrA trial and a decent prospect of a favourable phase 3 clinical trial.
There is also the phase 2 results CogniCann(R) - Phase II clinical trial evaluating the impact on dementia and Alzheimer's Disease patients. That should complete Q4.
Plenty of newsflow to come. I am not a big fan of investing in Company's with CLN's but any positive news from the CimetrA trial should outweigh that negative. I wouldn't be surprised to see a run-up in anticipation of the CimetrA results.
Pokerchips, there appears to be some guesswork / misinformation in your post. From the announcement on 7th July. They have announced the trial has begun so they are on track. The timeframes may be a bit tight depending on recruitment but not as extended as you have indicated. They have multiple trial sites in Israel and Brazil for recruitment. Regardless, it looks like results in Autumn this year.
From the announcement dated 7th July :-
" Expected duration: The trial is expected to commence in the coming week and conclude around September 202 1 with
results then available in October 2021. "
I can see this having a decent run as the herd move in for the phase 3 trial results in the Autumn. Should be an update or two prior to starting as they get the trial recruitment numbers. Now they have the centres in Brazil they should be able to reach the numbers reasonably quickly.
It's an important trial from a global health perspective and, accordingly, it should get plenty of media attention as well.
Very short trial (about one month I believe) and relatively low risk given all the favourable results so far, although no phase 3 is without risk of course. Hard to say where it could move to if successful in the trial, but back to the highs from the UK listing levels would be nice.
Yes the FD might as well have been wearing a hoodie and headphones. He was slumped in his chair and tapping on his phone for the entire meeting. I couldn't believe it and the brevity of his answers and disinterest either indicates an embarrassment with his poor English or just pure arrogance and inappropriate behaviour for someone who represents a publicly listed company.
MR did try to explain the absence of any upbeat tone by saying STAR wants to under promise and over deliver and it had been a difficult time for everyone due to Covid-19. He said they had previously done the opposite 'been there and done that before' and implied that approach back-fired. He also explained that there were pandemic issues such as difficulty with supplies that meant things had been difficult. He balanced that by saying hopefully that will change in due course. I think with the previous slap on the wrist for dubious accountancy reporting he now errs on the side of caution. He wouldn't be happy with the Rosenberg name being associated with anything untoward and wants to come across as circumspect and small c conservative. Also, he doesn't have much skin in the game although he may have a decent slug of options.
The negative tone is undoubtedly depicting past and present but they should have balanced that with what looks like potentially good prospects for a lokies contract going forward. On that product was there really any need for MR to say the DHL pilot trials are very, very early stage? Maybe having mentioned Bosch and the United Nations potential contracts previously and nothing material developing he is under-stating for the same reasons as above; a desire to be a cautious realist and hopefully under-promising and over delivery?
The issue of STAR being unduly negative might be for the above 'realism' reasons but they have to watch their negative tone as cynics might point to the fact that two thirds of salaries / fees of the Chairman are being paid in shares each month. Obviously the lower the share price the more shares received. I doubt that but ...
STAR have been brilliant at managing cash resources and maintaining superb R&D technical innovations and upgrades with such limited funds. Cash must be tight now so I'd be very disappointed if they raised at current levels with such a downbeat statement and presentation. I'd like directors to take part but the downbeat tone wouldn't sit well with me if they did. Perhaps they will await the potential Lockies contract and, if that materialises, then they would either not have to raise or could do so at a significantly higher price. Regardless, whilst conscious of costs and continuity, they need a decent PR company and perhaps a more dynamic chairman who can give a more upbeat tone. The Company has to be worth a lot more for its IP and product range and surely even on a small revenue multiple has to be worth much more and be of interest to third parties.
Very unprofessional presentation. Wasn't impressed with seeing the FD slumped in his chair playing on his 'phone. What on was he doing? When Michael Rosenberg tried to engage him he gave monosyllabic disinterested answers. The statement was so poorly worded as if they wanted the share price to go down.
Before the meeting they were discussing share holdings and one of the board told Michael R he had 1.5m shares. MR questioned that and they were mumbling something about more being in nominee.
They need someone PR savvy to help them out unless they actually temporarily want a lacklustre share price to get a funding away. Rosenberg did his best but he doesn't have much skin in the game and, without wishing to be harsh, is past his sell by date and doesn't impart the right image for a high tech innovative company Company. I think he probably writes the newsflow as well as the others have broken English at best. Perhaps the board will participate in any raise and we might get some more positive vibes after then. The way this was done goes way below amateur and contrasts with the excellent product innovation and success on a tight budget that they have achieved. They must have done a much better presentation to DHL. Very disappointing and odd.
No, it's actually about £50m m/cap with currently 2,319,502,595 shares in issue.
Interesting company but with a lot of 'unsticky' shares issued to various parties causing an overhang with more shares to be issued imminently. The parties who receive the shares appear to have an interest in the share price being as low as possible as the number of shares they receive is based on a 10 day average share price. Timing entry here could pay off but it looks like the overhang will be around for about 9 months until all the shares for the acquisition have been issued. Last issue looks to be May 2022. That's my reading of it anyway but happy to be corrected and dyor etc. Who knows, great news from clinical trials could change what looks like the trend and overhang.
The imminent new shares relate to the recent GM announcement and the issue of shares in stages for the acquisition of MediCaNL for AU $6m as detailed in the April acquisition rns.
"The consideration for the Acquisition is $6,000,000 in MXC shares, based on the volume weighted average price per share of the Company calculated on a 10-day VWAP from settlement, with 30% of the consideration shares to be issued at settlement (under the Company's existing Listing Rule 7.1 placement capacity) and the remaining 70% (the Deferred Consideration) to be issued in instalments as follows (subject to shareholder approval):
(a) 20% on the date which is 4 months from the date of settlement;
(b) 20% on the date which is 7 months from the date of settlement;
(c) 20% on the date which is 10 months from the date of settlement; and
(d) 10% on the date which is 13 months from the date of settlement, "
I contacted the Company's advisors (Luther Pendragon) about the absence of an rns on the covid-19 detection machine trials in the context of the CEO, Dr Basu, saying results would be forthcoming in the 'coming days' and had this reply copied below. Whilst , as you'd expect, no specific date is given, I think it bodes well for a potential release of the Covid trial results either with the financials on the 14th or close to that date. It's also telling that clips emphasising the initial current positives from the trial were also detailed in the reply.
"Kromek is committed to keeping shareholders abreast of significant developments and fully intends to provide an update on the trials and the status of the bio-threat detection solution via RNS as appropriate.
Over the last few weeks, the company has commented on the positive results being achieved at trials in a number of locations: Newcastle Airport, Teeside Airport, Durham School and St Mary’s ****erton School. You can find further details in news clips linked below.
https://youtu.be/LqvE2Mvhy_8
https://youtu.be/Eb-p-MDgjAg
https://youtu.be/y6wohFSPHSY